CNBC Pro

Betting on biotech during JPMorgan's big health-care conference pays off, history shows

Morsa Images | Getty Images

Buying the biotech ETF during JPMorgan's annual health-care conference, the industry's biggest gathering, has proven to be a profitable trade, according to research by the investment bank.

"Biotech has historically outperformed the broader market during The J.P. Morgan Healthcare Conference," biotech analysts at the firm wrote in a note to clients ahead of the event, which will take place Jan. 9-12 in San Francisco.

In the past 16 years, the NYSE Arca Biotechnology index (BTK), which measures the performance of 30 biotechnology firms, has outperformed the by nearly 3 percent during JPMorgan's conference, research by the firm shows.

"We observed that the BTK has outperformed the S&P 500 during JPM week ~81 percent of the time (all but three years)," the report said.

NYSE Arca Biotechnology vs. S&P 500 (Performance during JPMorgan's health-care conference)


Source: JPMorgan

Investors often pay close attention to biotech companies presenting at the event as stock-moving information is often released, including earnings guidance and updates on drug developments.

(Editor's note: CNBC's Meg Tirrell will be interviewing some of the top CEOs from the conference next week, including Sarepta's Dr. Ed Kaye, exclusively for CNBC PRO.)

Here are some of the companies JPMorgan believes investors "can't miss" and the reasoning from analysts as to why those stocks could move.

More In Pro News and Analysis

CNBC ProThese stocks are so cheap, they're good buys even if earnings take a hit, Trivariate Research says
CNBC ProMeet the veteran growth investor who picks stocks like Warren Buffett
CNBC ProThe grand 'work from anywhere' experiment got a few things wrong. Here's how companies are fixing it.